Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To make intravenous (IV) ganciclovir available to immunocompromised patients with
life-threatening or sight-threatening Cytomegalovirus (CMV) infection, where the symptoms of
the disease are too severe to allow admission to a controlled clinical study of ganciclovir
therapy. To determine the safety and tolerance of 2 - 3 weeks induction course of ganciclovir
IV followed by a maintenance course of ganciclovir IV for an indefinite duration. To tabulate
the patient's clinical response.